Tumor vessel normalization, achieved through targeting glycolytic enzymes like PFKFB3 176, PKM2 177, TRPM7 178 and PDK 179 emerges as a promising anticancer strategy by improving vessel maturity and perfusion, thereby reducing tumor aggressiveness and enhancing chemotherapy effectiveness. The gene discussed is PKM; the disease is neoplasm.